Literature DB >> 1385052

Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease.

P D Piccioni1, J A Kramps, A Rudolphus, A Bulgheroni, M Luisetti.   

Abstract

In order to characterize the imbalance between proteinases and proteinase inhibitors in sputum sol phases, we studied 25 patients (mean age, 59 +/- 11 yr) with exacerbated chronic obstructive pulmonary disease (COPD). An aliquot of sputum was used for bacteriologic determinations, and the remainder was centrifuged in order to obtain gel and sol phases. On the basis of the bacteriologic data, patients were divided into colonized patients (14) and noncolonized patients (11). All of the major inhibitors were immunologically detectable in sol phases without a significant difference between colonized and noncolonized patients (alpha 1-proteinase inhibitor [alpha 1-PI], 2.56 microM +/- 0.53 microM and 2.39 microM +/- 0.72 microM; alpha 2-macroglobulin [alpha 2-MG], 0.21 microM +/- 0.07 microM and 0.16 microM +/- 0.05 microM; antileukoprotease (ALP), 1.78 microM +/- 0.57 microM and 1.53 microM +/- 0.6 microM, respectively [mean +/- SE]). With regard to proteinase activities, both free elastase-like and free chymotrypsin-like activities were detectable in the majority of patients (15/25) (0.59 microM +/- 0.15 microM and 0.74 microM +/- 0.15 microM for elastase-like activity [ELA], and 0.010 microM +/- 0.003 microM and 0.017 microM +/- 0.007 microM for chymotrypsin-like activity [CLA], respectively [mean +/- SE]). The inhibitory profile of proteinase activities, performed by means of a panel of inhibitors, allowed us to assign specific activities mainly to neutrophil elastase and cathepsin G (Cat G). Next we looked at the relationships between inhibitors and proteinase activities. We found a significant negative correlation between neutrophil elastase activity and ALP (r = -0.58; p < 0.01). In confirmation of this suggestion, sol phases were divided into samples (15) with detectable ELA (> 0.50 microM) and samples (10) with no detectable ELA (< 0.18 microM). Levels of alpha 1-PI and alpha 2-MG did not differ significantly between the two groups, whereas ALP values were higher in the group with no detectable ELA (3.12 microM +/- 0.69 microM) than in the other group (0.58 microM +/- 0.21 microM; p < 0.001). We conclude that most sputum sol phases from patients with exacerbated COPD have a high burden of free neutrophil elastase and Cat G. Antileukoprotease seems to be the major naturally occurring inhibitor effective in the modulation of proteinase activities in bronchial secretions under these conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385052     DOI: 10.1378/chest.102.5.1470

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion.

Authors:  Robert Tarran; Juan R Sabater; Tainya C Clarke; Chong D Tan; Catrin M Davies; Jia Liu; Arthur Yeung; Alaina L Garland; M Jackson Stutts; William M Abraham; Gary Phillips; William R Baker; Clifford D Wright; Sibylle Wilbert
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-29       Impact factor: 5.464

2.  Pharmacological activities of TEI-8362, a novel inhibitor of human neutrophil elastase.

Authors:  H Mitsuhashi; T Nonaka; I Hamamura; T Kishimoto; E Muratani; K Fujii
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

3.  5,9,23-Triacontatrienoic methyl ester, an elastase inhibitor from the marine sponge Chondrilla nucula.

Authors:  Michèle Meyer; Michèle Guyot
Journal:  Lipids       Date:  2002-11       Impact factor: 1.880

4.  Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.

Authors:  K Masuda; T Kamimura; K Watanabe; T Suga; M Kanesaki; A Takeuchi; A Imaizumi; Y Suzuki
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

5.  Neutrophil elastase and endogenous inhibitors in Behçet's disease saliva.

Authors:  T Novak; F Fortune; L Bergmeier; I Khan; E Hagi-Pavli
Journal:  Clin Exp Immunol       Date:  2020-07-29       Impact factor: 4.330

6.  Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex.

Authors:  Anita L Sullivan; Timothy Dafforn; Pieter S Hiemstra; Robert A Stockley
Journal:  Respir Res       Date:  2008-08-12

7.  Susceptibility of lung epithelium to neutrophil elastase: protection by native inhibitors.

Authors:  L Bingle; R J Richards; B Fox; L Masek; A Guz; T D Tetley
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.